Study results included a total of 1,461,540 patients with cancer, with 881,692 patients from expansion states and 579,848 patients from non-expansion states. After adjusting for sociodemographic ...

Breast density is a measure of the amount of fibrous and glandular tissue compared with fat tissue in a woman’s breasts. The average U.S. woman’s risk of developing breast cancer is about 13%. Women ...

The development of a new FDA-approved drug begins somewhere in a laboratory, trying to figure out exactly what’s needed at the cancer cell level and looking at it in preclinical models. The first step ...

Combining standard adjuvant chemotherapy with the immune checkpoint inhibitor atezolizumab [Tecentriq] leads to a significant improvement in disease-free survival in a subset of patients with Stage ...

As their first-line treatment, people with HR-positive, HER2-negative advanced breast cancer often receive hormone therapy—most commonly an aromatase inhibitor—given in combination with a CDK4/6 ...

A new study by researchers at the American Cancer Society (ACS) shows that a higher county-level share of medical debt in collections was associated with delays in treatment initiation among ...

“I am truly honored to receive the 2025 Excellence in Engagement Award,” said Dr. Abu-Rustum. “It has been a privilege to represent Memorial Sloan Kettering Cancer Center through my ongoing work with ...

“They were able to gobble up the chemotherapy and chemically transform it into a harmless byproduct,” said Kai Trepka, a student in the Medical Scientist Training Program at UCSF who co-authored the ...

A pre-surgical combination therapy including pembrolizumab [Keytruda] plus dabrafenib [Tafinlar] and trametinib [Mekinist] (DTP) significantly improved survival in patients with rare BRAF ...

Using artificial intelligence (AI) assistance can help pathologists more accurately classify breast cancer with low levels of HER2 expression and reduce the risk of misclassifying HER2-low and ...

Overall, people who used GLP-1 agonists had a 7% lower risk of developing obesity-related cancers than those who used DPP-4 inhibitors. The effect was more pronounced for women, who had an 8% lower ...

The three most prevalent cancers are prostate (3,552,460), melanoma of the skin (816,580), and colorectal (729,550) among males and breast (4,305,570), uterine corpus (945,540), and thyroid (859,890) ...